PURSUING A POTENTIALLY TRANSFORMATIVE CANCER TREATMENT APPROACH

Kalson Biotech is a clinical stage biotechnology company pioneering the development of Reitec DSAR T (DSAR T^TM) therapies for cancer and Anti-Inflammatory Perfumes. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” DSAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.

We BELIEVE

We believe the next revolution in cancer treatment is the development of DSAR T^TM therapies engineered from the T cells of healthy donors. These off-the-shelf DSAR T therapies and perfumes enhanced by gene editing could be the next most important breakthrough in the field. Our mission is to catalyze this immune cell therapy approach and deliver DSARs^TM to patients with hematologic cancers and solid tumors to make a difference in their lives.

Our expertise at your disposal

Drawn from a wide range of pharmaceutical industry backgrounds, our dedicated team is highly experienced in the design, development and industrialisation of drug product manufacturing.
Alongside our expertise in sterile filling, our team of experienced pharmaceutical scientists will handle process development, testing and validation, and our QP can release supplies to the clinic.
We have in-house Technical, Validation, Documentation, Quality Control and Quality Assurance teams, all dedicated to providing our clientele with a fast, flexible and high-quality service.

Fairfax, Virginia U.S HQ (Operations) :

Henry Job, PhD

CEO/Managing Director - Dr. Henry a Ph.D. in Medicinal Chemistry from the State University of New York, was awarded an NIH postdoctoral fellowship in natural products synthesis and structure elucidation at the University of Pennsylvania, and holds a B.S. magna cum laude in chemistry from the University of South Florida.

Allbright Research Center (Canada):

Thompson Washington, PhD

Manager - Dr. Thompson received both his Ph.D. in medicinal chemistry and his B.S. in Healthcarecy from the University of Kansas, and he completed post-doctorate training in synthetic organic chemistry at Indiana University.

Canada Research Center (Generic):

Maddock Paul;, M.D.

Dr. Maddock received his training in oncology and hematology at the University Hospital Charité in Berlin with research activities focused on hematological malignancies and bone marrow transplantation. Prior to his clinical training, Dr. Madison participated in a post-doctoral program in Molecular and Cellular Biology at the University of Hamburg. Dr.Gross holds an M.D. from the University of Cologne, Germany.

Phyto Chemicals

Aylar Mascarenhas, PhD

Dr. Aylar served as Senior Director, Technology Development & Operations at ViroHealthcare Inc., prior to and following its acquisition by Shire plc. Prior to joining ViroHealthcare, she served in CMC leadership roles of increasing responsibility at Elan Corporation plc, Merck & Co., Inc., NanoSystems LLC and Sterling Winthrop Healthcareceuticals. Dr. Baris earned a B.S. in Healthcarecy and a Ph.D. in Healthcareceutics, both from The University of North Carolina at Chapel Hill.